drugset / Trial / NCT03852654

18F-DCFPyL PET-CT Scan and Prostate Cancer

NCT03852654

NaSingle-groupOpen-labelDiagnostic

Summary

Primary Objective: The primary objective of this study is to assess the efficacy of 18F-DCFPyL PET-CT for initial staging of prostate cancer in Veterans compared to conventional imaging (99mTc-MDP bone scan and Diagnostic CT or MRI). The primary clinical endpoint of our study is the percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease at initial staging. Secondary Objectives: Frequency of the change in primary treatment plan after initial staging.

Timeline

Start
2018-07-22
Primary completion
2019-12-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-DCFPyL Diagnostic / imaging agent